<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065751</url>
  </required_header>
  <id_info>
    <org_study_id>2786-2015</org_study_id>
    <nct_id>NCT03065751</nct_id>
  </id_info>
  <brief_title>Plasmaexchange in Early Septic Shock</brief_title>
  <acronym>EXCHANGE</acronym>
  <official_title>Prospective, Randomized, Multicenter, Open-label, Controlled, Parallel-group Trial Investigating the Efficacy of add-on Plasma-exchange as an Adjunctive Strategy Against Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hannover Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is defined by the occurrence of a systemic inflammatory response syndrome (SIRS) in&#xD;
      the context of infection. Unfortunately, its incidence appears to be rising, and the&#xD;
      mortality of septic shock remains extraordinary high (&gt; 60%). Death in sepsis arises from&#xD;
      shock and multi organ dysfunction that are - at least in part - triggered by an inadequate&#xD;
      response of the host's immune system to the infection. Given the injurious role of 1) this&#xD;
      overwhelming immune response and 2) the consumption of protective plasmatic factors (e.g. vWF&#xD;
      cleaving proteases, hemostatic factors etc.) while the disease is progressing the&#xD;
      investigators hypothesize that early therapeutic plasma exchange (TPE) in the most severely&#xD;
      ill individuals might improve hemodynamics, oxygenation and ultimately survival. This&#xD;
      therapeutic strategy combines 2 major aspects in 1 procedure: 1. removal of harmful&#xD;
      circulating molecules and 2. replacement of protective plasma proteins. The investigators&#xD;
      designed the EXCHANGE trial to analyze in a randomized fashion the benefit of TPE as an&#xD;
      add-on treatment to state of the art standard sepsis care. Only patients with early septic&#xD;
      shock (&lt; 12 hrs) and high catecholamine doses (noradrenaline &gt; 0.4 ug/kg bodyweight/min) will&#xD;
      be included. Those in the treatment group will receive 3 TPEs within three consecutive days.&#xD;
      The primary outcome is 28-day all cause mortality. To show an assumed reduction from 60% to&#xD;
      45% in the experimental group, a sample size of 173 patients per group has been calculated.&#xD;
      The overall sample size is therefore n=346. The recruitment period is 3 years (+3 months&#xD;
      observation) and will be performed in 11 national centers in Germany. Secondary endpoints&#xD;
      (including hemodynamics, oxygenation, coagulation, and microcirculation) will be assessed on&#xD;
      day 1, 2, 3 before and after TPE and on day 4, 5, 7 and 14.&#xD;
&#xD;
      Project management and data monitoring will be organized by the Hanover Clinical Trial Center&#xD;
      and biostatistics including a web-based randomization will be performed by the Institute of&#xD;
      biometrics (Prof. Koch) at Hannover Medical School.&#xD;
&#xD;
      The investigators hope to demonstrate a potential benefit of an additive treatment approach&#xD;
      to improve the outcome of patients suffering from an under-recognized but deadly disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Overall mortality</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>TPE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Kontroll</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasmaexchange</intervention_name>
    <description>TPE against fresh frozen plasma</description>
    <arm_group_label>TPE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Onset of septic shock within less than 12 hrs&#xD;
&#xD;
          -  Noradrenaline dose of ≥ 0.4 ug/kg/min bodyweight (target MAD ≥ 65 mmHg) ≥ 30 min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;18 years and &gt; 80 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known history of transfusion reactions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sascha David, MD</last_name>
    <phone>0049 511532</phone>
    <phone_ext>9357</phone_ext>
    <email>david.sascha@mh-hannover.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haller Hermann, MD</last_name>
    <phone>0049 511532</phone>
    <phone_ext>6319</phone_ext>
    <email>nephrologie@mh-hannover.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hannover Medical School</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sascha David, MD</last_name>
      <phone>0049 511532</phone>
      <phone_ext>9357</phone_ext>
      <email>david.sascha@mh-hannover.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>pre-defined substudies with primary responsibilities for each individual center</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

